Company Profile
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company provides the research, development, and commercialization of novel antibody drugs globally. It develops therapies in oncology, autoimmune, and severe diseases.
The company's lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma. Its portfolio also includes LBL-007, a novel anti-LAG-3 antibody designed to restore T-cell activity, and LBL-034, a novel GPRC5D-targeting T-cell engager for anti-tumor activity.
Additionally, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinical studies X-body platform, a 4-1BB/PD-L1 bispecific antibody. Founded in 2012, the company is headquartered in Nanjing, China.